Tags: lung cancer
Highlights in Lung Cancer
Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer The use of osimertinib (Tagrisso, AstraZeneca) after surgery improves overall survival (OS) in patients with early-stage, EGFR-mutated […]
Hem/Onc News
Duvelisib Approved in Relapsed/Refractory CLL, SLL, and FL The US Food and Drug Administration (FDA) approved duvelisib (Copiktra, Verastem) on September 24 for adults with relapsed […]
Hem/Onc News
Pembrolizumab Receives Regular Approval in Metastatic Nonsquamous NSCLC On August 20, the US Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda, Merck) for […]
How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver
Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]
Optimal Treatment of Unresectable Stage III Non–Small Cell Lung Cancer
Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Jeffrey D. Bradley, MD S. Lee Kling Professor of Radiation Oncology Alvin J. Siteman […]
HSP90 Inhibitors in Lung Cancer: Promise Still Unfulfilled
Abstract: Despite recent advances in the treatment of lung cancer, non–small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the United States […]